landomycin E

structure given in first source; isolated from Streptomyces sp.

Networked: 3 relevant articles (0 outcomes, 2 trials/studies)

1.	T-Cell Leukemia (Leukemia, T Cell) 01/01/2017 - "In the present study, cellular and molecular mechanisms underlying the anticancer activity of landomycin E towards Jurkat T-cell leukemia cells were dissected focusing on the involvement of radical oxygen species (ROS). "
2.	Neoplasms (Cancer) 12/01/2005 - "The aim of the present study was to investigate regulation of mRNA, coding for TGFbeta ligands and specific receptors, by novel antitumor antibiotic landomycin E (LE) in human breast adenocarcinoma cells of MCF-7 line, sensitive and resistant to anti-cancer agent doxorubicin. "
3.	Adenocarcinoma 12/01/2005 - "The aim of the present study was to investigate regulation of mRNA, coding for TGFbeta ligands and specific receptors, by novel antitumor antibiotic landomycin E (LE) in human breast adenocarcinoma cells of MCF-7 line, sensitive and resistant to anti-cancer agent doxorubicin. "
4.	Hypoxia (Hypoxemia) 11/25/2021 - "Accordingly, landomycin E strongly synergized with glutathione-depleting agents like menadione but exerted reduced activity under hypoxia. "

1.	Reactive Oxygen Species (Oxygen Radicals)
2.	Transforming Growth Factor beta (TGF-beta)
3.	Messenger RNA (mRNA)
4.	Ligands
5.	Doxorubicin (Adriamycin)
6.	Anti-Bacterial Agents (Antibiotics)
7.	Vitamin K 3 (Menadione)
8.	Glutathione (Reduced Glutathione)